Free Publications

Search for cll returned 193 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

Patient Support Programs - California Southland

The Leukemia & Lymphoma Society's California Southland Chapter offers a wide range of free educational and support programs for patients, their families, caregivers and healthcare professionals.

For more information about any of the following programs or upcoming educational programs, please contact: Leila Evangelista
Patient Access Manager
310.846.4704
leila.evangelista@lls.org  
Patti Robinson Kaufmann First Connection Program If you've ...

  • Photo
Read more

Looking Ahead: LLS Panel Highlights Trends and Advances

The Leukemia & Lymphoma Society recently brought together a world-renowned panel of thought leaders to discuss the latest advances and insights into blood cancer research and treatment, drug costs and patient access, and patient advocacy and policy.

 “There’s never a good time to get cancer but this is a phenomenal time to be fighting it,” said Louis J. DeGennaro, president and CEO of The Leukemia & Lymphoma Society (LLS).

Read more

LLS Helps Patients and Caregivers Find Online Support and Health Information

- LLS Community grows to nearly 5,000 users in one year -
- New collaboration with Medivizor will provide patients and caregivers with personalized, accurate and easy-to-understand medical information - Rye Brook, N.Y. (June 15, 2017) – LLS Community, a free online network providing support and education to blood cancer patients and their caregivers, launched by The Leukemia & Lymphoma Society (LLS) in 2016, has proved to be a valuable resource for patients and caregivers, g ...

Read more

Record-Breaking Year for the Leukemia & Lymphoma Society's Man & Woman of the Year Campaign

Contact: Kristin Hoose
(914) 821-8973
kristin.hoose@lls.org White Plains, NY (July 17, 2014) - A Chicago man and Los Angeles woman raised $386,284 and $343,962, respectively, to support The Leukemia & Lymphoma Society's (LLS) mission to find cures for blood cancers and ensure that patients have access to lifesaving treatments.  As the leading fundraisers in the 2014 Man & Woman of the Year campaign, the 24th year for this prestigious program, these "Champi ...

Read more

Career Development Program (CDP)

.hide{ display:none} What it is. Career Development Program (CDP) grants support researchers early in their careers. The funding supports researchers at different stages of their career, from those with less than two years of postdoctoral research to those who hold independent faculty-level positions. The grants are designed to encourage these promising young investigators to embark on academic careers involving clinical or fundamental research in the blood cancers. What ...

  • Photo
Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.